36th floor, 300 Olympic-ro, Songpa-gu 05551 Seoul KR [email protected] Responsible person Nemo GMBH Mergenthaleralle 77 65760 Eschborn DE [email protected] +82 10-2695-3867 : AQUA, GLYCERIN, PEG-8, NIACINAMIDE, BUTYLENE GLYCOL, METHYLPROPANEDIOL, 1,2-HEXANEDIOL, METHYL GLUCETH-20, GLYCERETH-26, BIS-PEG-18 METHYL ETHER DIMETHYL SILANE, BETAINE, CARBOMER, DIPHENYL DIMETHICONE, TROMETHAMINE, TRIETHYLHEXANOIN, ETHYLHEXYLGLYCERIN, C12-14 ALKETH-12, PARFUM, GLUTATHIONE, XANTHAN GUM, HYDROGENATED LECITHIN, ADENOSINE, COPTIS JAPONICA EXTRACT, POLYGLYCERYL-10 OLEATE, DISODIUM EDTA, COLLAGEN, POLYGLYCERYL-10 LAURATE, SACCHARIDE HYDROLYSATE, PANTHENOL, THEOBROMA CACAO SEED EXTRACT, DEXTRIN, SODIUM HYALURONATE, STELLARIA MEDIA EXTRACT, SORBITAN LAURATE, PRUNELLA VULGARIS EXTRACT, LACTOBACILLUS FERMENT, FUCUS VESICULOSUS EXTRACT, HYDROXYETHYLCELLULOSE, ACETYL DIPEPTIDE-1 CETYL ESTER, EQUISETUM ARVENSE EXTRACT, CAPRYLYL GLYCOL, LYCOPODIUM CLAVATUM EXTRACT, HYALURONIC ACID, PALMITOYL TRIPEPTIDE-5, SODIUM HYALURONATE CROSSPOLYMER, HYDROLYZED SODIUM HYALURONATE, HYDROLYZED HYALURONIC ACID, ACETYL OCTAPEPTIDE-3, SODIUM ACETYLATED HYALURONATE, HYDROXYPROPYLTRIMONIUM HYALURONATE, HYDROLYZED KERATIN, HYDROLYZED COLLAGEN, HYDROLYZED SILK.
Hematopoietic cell- versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice
The IGF1 gene helps control how much IGF-1 the body makes, and natural differences in this gene may influence growth, recovery, and tissue repair signals
In NMO the myelin deteriorates mostly in the optic nerve, which can lead to blindness, and in the spinal cord
Here is a summary of the data for Utah : Share of all patients who take a GLP-1: 0.7% Share of patients with an obesity diagnosis who take a GLP-1: 4.8% Share of male patients with an obesity diagnosis who take a GLP-1: 4.4% Share of female patients with an obesity diagnosis who take a GLP-1: 5.1% Share of GLP-1 users that are female: 60.4% For reference, here are the statistics for the entire United States: Share of all patients who take a GLP-1: 1.0% Share of patients with an obesity diagnosis who take a GLP-1: 4.8% Share of male patients with an obesity diagnosis who take a GLP-1: 4.2% Share of female patients with an obesity diagnosis who take a GLP-1: 5.2% Share of GLP-1 users that are female: 64.7% For more information, a detailed methodology, and complete results, see U.S
Provider support helps patients navigate those decisions, achieve better outcomes, and, when appropriate, successfully reduce or discontinue medication over time
